MedPath

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase 2
Completed
Conditions
Childhood Extracranial Germ Cell Tumor
Childhood Malignant Ovarian Germ Cell Tumor
Childhood Malignant Testicular Germ Cell Tumor
Ovarian Yolk Sac Tumor
Recurrent Childhood Malignant Germ Cell Tumor
Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Ovarian Embryonal Carcinoma
Recurrent Malignant Testicular Germ Cell Tumor
Ovarian Choriocarcinoma
Recurrent Ovarian Germ Cell Tumor
Interventions
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Registration Number
NCT00467051
Lead Sponsor
Children's Oncology Group
Brief Summary

This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the response rate in pediatric patients with recurrent or resistant malignant germ cell tumors (GCT) treated with paclitaxel, ifosfamide, and carboplatin.

SECONDARY OBJECTIVES:

I. Determine the toxicity of this regimen in these patients. II. To Collect tissue for the tumor bank that will aid in the identification of the biological characteristics of recurrent GCT.

OUTLINE: This is a multicenter study.

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 5 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Histologically confirmed (at original diagnosis) extracranial germ cell tumor (GCT) containing 1 of the following malignant elements:

    • Yolk sac tumor (endodermal sinus tumor)
    • Choriocarcinoma
    • Embryonal carcinoma
  • Meets 1 of the following disease criteria:

    • Recurrent malignant disease
    • Chemotherapy-resistant disease
    • Relapsed disease
    • Disease refractory to conventional therapy
  • Measurable disease

  • Must have received a prior first-line chemotherapy regimen that included cisplatin

  • Patients with tumor marker (AFP and/or BHCG) elevation alone or bone scan findings alone are not eligible*

  • Patients with immature teratoma (any grade), germinoma, sex-cord stromal tumors, or recurrent GCT previously treated with surgery alone are not eligible

  • Karnofsky performance status (PS) 50-100% (age > 16 years) OR Lansky PS 50-100% (age ≤ 16 years) OR ECOG PS 0-2

  • Life expectancy ≥ 8 weeks

  • Absolute neutrophil count ≥ 750/mm³

  • Platelet count ≥ 75,000/mm³ (transfusion independent)

  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine normal based on age/gender, as defined by the following:

    • ≤ 0.4 mg/dL (1 month to < 6 months of age)
    • ≤ 0.5 mg/dL (6 months to < 1 year of age)
    • ≤ 0.6 mg/dL (1 to < 2 years of age)
    • ≤ 0.8 mg/dL (2 to < 6 years of age)
    • ≤ 1.0 mg/dL (6 to < 10 years of age)
    • ≤ 1.2 mg/dL (10 to < 13 years of age)
    • ≤ 1.4 mg/dL (13 to ≥ 16 years of age) (female)
    • ≤ 1.5 mg/dL (13 to < 16 years of age) (male)
    • ≤ 1.7 mg/dL (≥ 16 years of age) (male)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age

  • ALT < 2.5 times ULN for age

  • Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by gated radionuclide study

  • No dyspnea at rest

  • No exercise intolerance

  • Pulse oximetry > 94% (if there is clinical indication for determination)

  • Patients with seizure disorder are eligible provided they are on non-enzyme inducing anticonvulsants and seizures are well controlled

  • No CNS toxicity > grade 2

  • No active graft-versus-host disease

  • No allergy to Cremophor EL or castor oil

  • Not pregnant or nursing

  • Negative pregnancy test

  • Fertile patients must use effective contraception

  • No other concurrent chemotherapy or immunomodulating agents

  • Recovered from prior chemotherapy, immunotherapy, or radiotherapy

  • At least 1 week since prior growth factors (2 weeks for pegfilgrastim)

  • At least 1 week since prior biologic therapy

  • At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosourea)

  • At least 2 weeks since prior local palliative radiotherapy (i.e., small port)

  • At least 6 months since prior craniospinal radiotherapy or radiotherapy to ≥ 50% of pelvis

  • At least 6 weeks since other prior substantial bone marrow radiotherapy

  • At least 6 months since prior allogeneic stem cell transplantation

  • Concurrent radiotherapy to localized painful lesions allowed provided at least 1 measurable lesion is not irradiated

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Treatment (chemotherapy, biological therapy)FilgrastimPatients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Treatment (chemotherapy, biological therapy)Laboratory Biomarker AnalysisPatients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Treatment (chemotherapy, biological therapy)CarboplatinPatients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Treatment (chemotherapy, biological therapy)IfosfamidePatients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Treatment (chemotherapy, biological therapy)PaclitaxelPatients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measures
NameTimeMethod
Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) CriteriaAt baseline (day 1) and after completion of protocol therapy (2 cycles or 42 days)

Patients who demonstrate a PR or CR, as defined below, will be considered as responders. RECIST criteria: CR (complete response) = disappearance of all target lesions, PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions, PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions and SD (stable disease) = small changes that do not meet above criteria.

Secondary Outcome Measures
NameTimeMethod
The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity.Two cycles of chemotherapy; expected to be 42 days of treatment.

Trial Locations

Locations (95)

Cedars Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Children's National Medical Center

🇺🇸

Washington, District of Columbia, United States

Palmetto Health Richland

🇺🇸

Columbia, South Carolina, United States

West Virginia University Charleston Division

🇺🇸

Charleston, West Virginia, United States

Rainbow Babies and Childrens Hospital

🇺🇸

Cleveland, Ohio, United States

The University of Arizona Medical Center-University Campus

🇺🇸

Tucson, Arizona, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

Miller Children's and Women's Hospital Long Beach

🇺🇸

Long Beach, California, United States

Children's Hospital Los Angeles

🇺🇸

Los Angeles, California, United States

Lucile Packard Children's Hospital Stanford University

🇺🇸

Palo Alto, California, United States

Kaiser Permanente Downey Medical Center

🇺🇸

Downey, California, United States

Harbor-University of California at Los Angeles Medical Center

🇺🇸

Torrance, California, United States

University of Connecticut

🇺🇸

Farmington, Connecticut, United States

Alfred I duPont Hospital for Children

🇺🇸

Wilmington, Delaware, United States

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

MedStar Georgetown University Hospital

🇺🇸

Washington, District of Columbia, United States

Lee Memorial Health System

🇺🇸

Fort Myers, Florida, United States

Nemours Children's Clinic-Jacksonville

🇺🇸

Jacksonville, Florida, United States

Florida Hospital Orlando

🇺🇸

Orlando, Florida, United States

Nemours Children's Clinic - Pensacola

🇺🇸

Pensacola, Florida, United States

Nemours Children's Clinic - Orlando

🇺🇸

Orlando, Florida, United States

Johns Hopkins All Children's Hospital

🇺🇸

Saint Petersburg, Florida, United States

Sacred Heart Hospital

🇺🇸

Pensacola, Florida, United States

Children's Healthcare of Atlanta - Egleston

🇺🇸

Atlanta, Georgia, United States

Saint Mary's Hospital

🇺🇸

West Palm Beach, Florida, United States

Emory University Hospital/Winship Cancer Institute

🇺🇸

Atlanta, Georgia, United States

Lurie Children's Hospital-Chicago

🇺🇸

Chicago, Illinois, United States

University of Illinois

🇺🇸

Chicago, Illinois, United States

Advocate Children's Hospital-Oak Lawn

🇺🇸

Oak Lawn, Illinois, United States

Saint Jude Midwest Affiliate

🇺🇸

Peoria, Illinois, United States

University of Kentucky/Markey Cancer Center

🇺🇸

Lexington, Kentucky, United States

Norton Children's Hospital

🇺🇸

Louisville, Kentucky, United States

Tulane University Health Sciences Center

🇺🇸

New Orleans, Louisiana, United States

Children's Hospital New Orleans

🇺🇸

New Orleans, Louisiana, United States

Sinai Hospital of Baltimore

🇺🇸

Baltimore, Maryland, United States

Johns Hopkins University/Sidney Kimmel Cancer Center

🇺🇸

Baltimore, Maryland, United States

Helen DeVos Children's Hospital at Spectrum Health

🇺🇸

Grand Rapids, Michigan, United States

Spectrum Health at Butterworth Campus

🇺🇸

Grand Rapids, Michigan, United States

Hackensack University Medical Center

🇺🇸

Hackensack, New Jersey, United States

The Childrens Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

🇺🇸

New Brunswick, New Jersey, United States

Saint Joseph's Regional Medical Center

🇺🇸

Paterson, New Jersey, United States

Overlook Hospital

🇺🇸

Summit, New Jersey, United States

University of New Mexico Cancer Center

🇺🇸

Albuquerque, New Mexico, United States

Albany Medical Center

🇺🇸

Albany, New York, United States

Montefiore Medical Center - Moses Campus

🇺🇸

Bronx, New York, United States

Columbia University/Herbert Irving Cancer Center

🇺🇸

New York, New York, United States

State University of New York Upstate Medical University

🇺🇸

Syracuse, New York, United States

UNC Lineberger Comprehensive Cancer Center

🇺🇸

Chapel Hill, North Carolina, United States

Children's Hospital Medical Center of Akron

🇺🇸

Akron, Ohio, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

Children's Hospital of Pittsburgh of UPMC

🇺🇸

Pittsburgh, Pennsylvania, United States

Dayton Children's Hospital

🇺🇸

Dayton, Ohio, United States

Penn State Milton S Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Penn State Children's Hospital

🇺🇸

Hershey, Pennsylvania, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

East Tennessee Childrens Hospital

🇺🇸

Knoxville, Tennessee, United States

St. Jude Children's Research Hospital

🇺🇸

Memphis, Tennessee, United States

Driscoll Children's Hospital

🇺🇸

Corpus Christi, Texas, United States

Medical City Dallas Hospital

🇺🇸

Dallas, Texas, United States

Cook Children's Medical Center

🇺🇸

Fort Worth, Texas, United States

Covenant Children's Hospital

🇺🇸

Lubbock, Texas, United States

Children's Hospital of The King's Daughters

🇺🇸

Norfolk, Virginia, United States

Carilion Clinic Children's Hospital

🇺🇸

Roanoke, Virginia, United States

University of Alberta Hospital

🇨🇦

Edmonton, Alberta, Canada

British Columbia Children's Hospital

🇨🇦

Vancouver, British Columbia, Canada

IWK Health Centre

🇨🇦

Halifax, Nova Scotia, Canada

McMaster Children's Hospital at Hamilton Health Sciences

🇨🇦

Hamilton, Ontario, Canada

Children's Hospital of Eastern Ontario

🇨🇦

Ottawa, Ontario, Canada

Centre Hospitalier Universitaire Sainte-Justine

🇨🇦

Montreal, Quebec, Canada

Centre Hospitalier Universitaire de Quebec

🇨🇦

Quebec, Canada

San Jorge Children's Hospital

🇵🇷

San Juan, Puerto Rico

Massachusetts General Hospital Cancer Center

🇺🇸

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

🇺🇸

Houston, Texas, United States

University of Miami Miller School of Medicine-Sylvester Cancer Center

🇺🇸

Miami, Florida, United States

Indiana University/Melvin and Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Riley Hospital for Children

🇺🇸

Indianapolis, Indiana, United States

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Children's Hospitals and Clinics of Minnesota - Minneapolis

🇺🇸

Minneapolis, Minnesota, United States

Methodist Children's Hospital of South Texas

🇺🇸

San Antonio, Texas, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

University of Hawaii Cancer Center

🇺🇸

Honolulu, Hawaii, United States

CancerCare Manitoba

🇨🇦

Winnipeg, Manitoba, Canada

Sanford Broadway Medical Center

🇺🇸

Fargo, North Dakota, United States

Princess Margaret Hospital for Children

🇦🇺

Perth, Western Australia, Australia

UCSF Medical Center-Mount Zion

🇺🇸

San Francisco, California, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

Children's Hospital Colorado

🇺🇸

Aurora, Colorado, United States

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

🇺🇸

Denver, Colorado, United States

Saint Joseph's Hospital/Children's Hospital-Tampa

🇺🇸

Tampa, Florida, United States

Carolinas Medical Center/Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

UCSF Medical Center-Parnassus

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath